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Various K and Cl channels are important in cell
volume regulation and biliary secretion, but the specific
role of cystic fibrosis transmembrane conductance reg-
ulator in cholangiocyte cell volume regulation is not
known. The goal of this research was to study regulatory
volume decrease (RVD) in bile duct cell clusters (BD-
CCs) from normal and cystic fibrosis (CF) mouse livers.
Mouse BDCCs without an enclosed lumen were pre-
pared as described (Cho, W. K. (2002) Am. J. Physiol. 283,
G1320–G1327). The isotonic solution consisted of HEPES
buffer with 40% of the NaCl replaced with isomolar
amounts of sucrose, whereas hypotonic solution was the
same as isotonic solution without sucrose. The cell vol-
ume changes were indirectly assessed by measuring
cross-sectional area (CSA) changes of the BDCCs using
quantitative videomicroscopy. Exposure to hypotonic
solutions increased relative CSAs of normal BDCCs to
1.20  0.01 (mean  S.E., n  50) in 10 min, followed by
RVD to 1.07  0.01 by 40 min. Hypotonic challenge in CF
mouse BDCCs also increased relative CSA to 1.20  0.01
(n  53) in 10 min but without significant recovery.
Coadministration of the K-selective ionophore valino-
mycin restored RVD in CF mouse BDCCs, suggesting
that the impaired RVD was likely from a defect in K
conductance. Moreover, this valinomycin-induced RVD in
CF mice was inhibited by 5-nitro-2-(3-phenylpro-
pylamino)-benzoate, indicating that it is not from nonspe-
cific effects. Neither cAMP nor calcium agonists could
reverse the impaired RVD seen in CF cholangiocytes. Our
conclusion is that CF mouse cholangiocytes have defec-
tive RVD from an impaired K efflux pathway, which
could not be reversed by cAMP nor calcium agonists.
Under physiological conditions, osmoregulation plays a cru-
cial role in cholangiocytes, which are exposed to various os-
motic stresses from the uptake of solutes and electrolytes and
bile secretion (1, 2). A recent study on a human cholangiocar-
cinoma cell line (3), as well as our results in a study on primary
bile duct cell clusters (BDCCs)1 from normal mouse livers (4),
indicates that cholangiocytes can regulate their cell volumes
back to base line from hypotonicity-induced swelling. As in
other cell types, these adaptive mechanisms of regulatory vol-
ume decrease (RVD) in cholangiocytes are mediated by certain
K and Cl conductances (3, 4).
Cystic fibrosis (CF) is the most common inherited multisys-
tem disease in the Caucasian population and is caused by a
defect in the cystic fibrosis transmembrane conductance regu-
lator (CFTR). Many CF patients develop a spectrum of hepa-
tobiliary diseases that are thought to be due to secretory dys-
functions from the CFTR Cl channel defects. In recent years,
CF liver diseases have become the second most common cause
of mortality in CF patients as they live longer, but the under-
lying pathophysiological mechanisms are not well understood.
Recent immunocytochemical studies of the liver have shown
that CFTR is expressed only on the bile duct epithelium but not
on hepatocytes (5). The CFTR is one of the major Cl channels
mediating ion transport in the bile duct epithelium, but the
direct role of CFTR in osmoregulation in cholangiocytes is not
well known, although such defects in CFTR are likely to cause
defects in osmoregulation. Thus, the purpose of the present
study is to examine RVD in the cholangiocytes isolated from
Ctfr/ or CF mouse livers and compare it with RVD in
normal cholangiocytes. To accomplish this purpose, we have
used BDCCs, which are prepared by the same isolation method
as mouse isolated bile duct units (IBDUs) reported recently by
our laboratory (6) but lack the enclosed lumen of IBDUs. These
mouse cell preparations are primary cholangiocytes, and thus
are considered to be closer to the physiologic state than other
cholangiocyte cell lines and have proven to be quite powerful
tools for studying cholangiocyte biology and physiology. The
use of BDCCs can avoid likely problems with changes in lumi-
nal volumes with changes in osmotic solutions, and we have
successfully used these BDCCs to study RVD in normal cholan-
giocytes (4).
In the present study, we present compelling evidence that,
unlike normal mouse BDCCs, those from Cftr/ mouse livers
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have an impaired RVD as suspected from the defect in CFTR.
Surprisingly, however, the impaired RVD in these CF BDCCs
is mainly caused by defects in K conductances, rather than
Cl conductances, and is thus restored when K conductances
are provided by valinomycin, a K ionophore. In addition, the
observed RVD of CF BDCCs during administration of valino-
mycin is inhibited by NPPB, a general chloride channel
blocker, indicating that the effects of valinomycin are not from
nonspecific effects of valinomycin. In addition, these findings
also indicate that there is a functioning non-CFTR chloride
conductance pathway(s) present in CF cholangiocytes, which
can mediate RVD in these cells.
EXPERIMENTAL PROCEDURES
Materials—Bovine serum albumin, penicillin/streptomycin, EDTA,
heparin, HEPES, D()-glucose, insulin, dimethyl sulfoxide (Me2SO),
hyaluronidase, and deoxyribonuclease (DN-25) were purchased from
Sigma. Matrigel was from Collaborative Biomedical (Bedford, MA),
collagenase D was from Roche Applied Science, and Pronase was from
Calbiochem. Liebowitz-15 (L-15), minimum essential medium, -mini-
mum essential medium, L-glutamine, gentamicin, and fetal calf serum
were from Invitrogen. Monoclonal anti-cytokeratin 19 antibodies were
from Amersham Biosciences. The CFTR antibody was a generous gift
from Dr. Christopher Marino. All other chemicals were of the highest
purity commercially available.
Solutions—The compositions of the Krebs-Ringer bicarbonate and
HEPES buffer solutions (containing (in mM) 135 NaCl, 4.7 KCl, 1.2
KH2PO4, 1.25 CaCl2, 10 HEPES, 1 MgSO4, 5 glucose, pH 7.4, 37 °C)
have been described previously (7, 8). Isotonic and hypotonic solution
compositions are as described previously (4). The isotonic solution was
made by replacing 40% of the NaCl in the HEPES solution (pH 7.4 at
37 °C) with an equimolar amount of sucrose. The hypotonic solution
was made the same as the isotonic solution but without sucrose. The
actual osmolarities of the solutions used were determined by a vapor
pressure osmometer 5500 (Wescor, Inc., Logan, UT).
Isolation of Bile Duct Cell Cluster—The male Cftr/ mice at age
4–14 weeks were obtained from Dr. Bev Koller at the University of
North Carolina. Control normal male C57BL6 mice at the same ages
were obtained from the Harlan Laboratory (Indianapolis, IN). These
mice were housed and allowed free access to Colyte-supplemented wa-
ter and Purina rodent chow (St. Louis, MO) to minimize complications
of intestinal obstruction described previously (9, 10). Animal care and
studies were performed in compliance with institutional animal care
and use committee guidelines. Mouse BDCCs were prepared as previ-
ously described (4, 6). Briefly, mice were prepped and anesthetized, and
their portal veins were perfused with Hanks’ buffers with collagenase
B; then the liver was harvested as described (4, 6). The non-parenchy-
mal tissue was obtained by removing the hepatic capsule and then
mechanically dissociating hepatocytes. The non-parenchymal tissue
was finely minced with scissors and then further digested serially by
various enzymes including collagenase, DNase, and Pronase or hyalu-
ronidase in modified minimum essential medium solution as described
previously (4, 6). After each serial enzymatic digestion step, fragments
were filtered through 100- and 30-m meshes (Tetko, Lancaster, NY),
and those remaining on the 30-m mesh were collected in 3–6 ml of
modified -minimum essential medium plating medium as described (4,
6). Fragments were then plated on small coverslips (2–4 mm), coated
with Matrigel (Collaborative Research) in 12-mm-diameter tissue cul-
ture wells (Corning), and incubated at 37 °C in an air/5% CO2-equili-
brated incubator. Experiments were carried out 36–56 h after plating.
Cell viability was assessed by trypan blue exclusion in plated BDCCs at
the end of the functional studies.
Characterization of Mouse BDCC—Immunocytochemistry using cy-
tokeratin-19 or CFTR antibody (6, 8, 11) was performed in BDCCs
48–72 h after plating. Immunofluorescent images of the mouse BDCCs,
immunostained with cytokeratin-19 or CFTR antibody, were obtained
using an Olympus IX-70 inverted fluorescent microscope (Olympus
America, Inc., Melville, NY) with a cooled charge-coupled device video
camera (Hamamatsu Photonics Systems, Bridgewater, NJ) connected
to a Power Mac computer with image analysis software (Improvision,
Inc., Boston, MA).
Quantitation of Regulatory Volume Response with Videomicroscopy—
Applying the methods used for measuring a cross-sectional area (CSA)
of hepatocytes and cholangiocytes (12) as well as other cell types (13),
we recently have shown and validated that the CSA measurements of
mouse BDCCs obtained by quantitative videomicroscopy were highly
correlated (linear correlation coefficient, r2  0.94) with the cell volume
measurements by 3 independent methods: 1) sequential Nomarski
light, 2) fluorescence microscopy of BDCCs loaded with BCECF and
computer-assisted measurements of the corresponding CSA and vol-
umes, and 3) laser-scanning confocal microscopy of intracellular fluo-
rescent dye, BCECF-loaded BDCCs, and computer-assisted three-di-
mensional reconstruction and volume calculation (4). Thus, in the
present study, the CSA measurements of BDCCs by quantitative video-
microscopy were used as indirect indices of cell volume measurements.
BDCCs cultured overnight on Matrigel-coated glass coverslips were
preincubated in isotonic solution for 10–20 min after being placed in a
thermostated specimen chamber on a microscope stage. Coverslips were
scanned for 5–10 min to select relatively spheroid BDCCs with sharp
borders and without connections to other contiguous BDCCs and with-
out any enclosed lumen. Videoimages of these BDCCs were obtained at
1–5-min intervals while maintaining the same focal plane at the max-
imum cross-sectional area. Osmoregulatory responses of BDCCs were
determined by assessing the changes in CSA of BDCCs using an Olym-
pus IX-70 (Olympus America) or a Leica DMIR (Leica Microsystems,
Inc., Bannockburn, IL) inverted microscope with Nomarski optics
equipped with a CCD video camera (Hamamatsu Photonics Systems)
connected to a computer with OpenLab image analysis software (Im-
provision). Following a 10–20-min prestimulation period with isotonic
HEPES buffer alone, BDCCs were exposed to a hypotonic HEPES
buffer for 40 min with or without various inhibitors or chemicals dis-
solved in the solution. Each BDCC served as its own internal control,
and changes in the cross-sectional area were expressed as a percentage
of base-line values at time 0. The viability of each BDCC was assessed
by the addition of trypan blue to the specimen chamber after each
experiment. The BDCCs with positive trypan blue staining were ex-
cluded from data analysis. However, there was no significant change in
viability, assessed by trypan blue staining, in experimental groups
exposed to various inhibitors or chemicals compared with controls.
Statistical Analysis—All data from videomicroscopic measurements
are presented as the arithmetic mean  S.E., and cell purity and
viability are presented as the arithmetic mean  S.D. Statistical dif-
ferences were assessed by the unpaired or paired Student’s t tests using
the INSTAT statistical computer program (GraphPad Software, San
Diego, CA).
RESULTS
Characterizations of BDCCs—As with the BDCCs from nor-
mal mouse livers, BDCCs from Cftr/ mouse livers formed
spheroid clusters of cells with 24–48 h in culture (Fig. 1).
Viability of the BDCCs was over 95% as assessed by trypan
FIG. 1. Videomicroscopy of cystic fibrosis mouse bile duct cell
clusters with hypotonic maneuver. Normal (top panels) and CF
mouse BDCCs (bottom panels) were preincubated in modified isotonic
HEPES solution (40% of NaCl replaced with equimolar sucrose) and
then were exposed to hypotonic solution (isotonic solution without su-
crose) for 40 min. Both normal and CF mouse BDCCs swelled in hypo-
tonic solution by 20% within 10 min but, unlike normal BDCCs, CF
mouse BDCCs did not return toward their initial sizes with time,
indicating an impaired regulatory volume decrease.
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blue exclusion 24–72 h after culture. As with normal mouse
BDCCs characterized previously (6), these BDCCs from normal
and CF mouse livers were identified as bile duct epithelial cells
by positive immunocytochemistry using a cytokeratin-19 anti-
body, whereas negative controls with a secondary antibody
alone were consistently negative for immunostaining. As ex-
pected, the BDCCs isolated from Cftr/ mouse livers had no
significant immunostaining with the CFTR antibody, com-
pared with the negative controls, whereas BDCCs from normal
mouse livers had a bright CFTR immunostaining (Fig. 2).
Study of Regulatory Volume Decrease in Normal Mouse
Cholangiocytes—The osmolarity of the isotonic solutions,
measured by an osmometer, was 300.9  4.5 mosM (n  12,
mean  S.D.), and that of the hyposomolar solutions was
181.9  3.6 mosM (n  13). As shown in Fig. 1, BDCCs rapidly
and significantly increased in size within the first 10 min of
exposure to hypotonic solution. Exposing normal BDCCs to
hypotonic HEPES solution from isotonic HEPES solution
caused rapid increases in CSA as shown in Fig. 1, indicating
swelling of the cholangiocytes. Measurements of cross-sectional
areas using quantitative videomicroscopy showed that the rel-
ative CSA of normal BDCCs rapidly increased to 1.20  0.01
(mean  S.E.; n  50) in 10 min after exposure to hypotonic
HEPES solution (Fig. 3) and then gradually returned toward
1.07  0.01 of initial CSA over the next 30 min. Previous work
from our laboratory has confirmed that CSA measurements of
BDCCs accurately (correlation coefficient r2  0.94) reflect
their corresponding cell volume measurements using sequen-
tial phase-contrast and fluorescence microscopy of BCECF-
loaded BDCCs as well as by laser-scanning confocal microscopy
followed by three-dimensional volume measurement analysis
(4). These results are consistent with the previous studies on
Mz-ChA-1 cells from human cholangiocarcinoma cell lines (3)
and normal BDCCs (4) that showed cholangiocytes exhibit
intact regulatory volume decrease after exposure to a hypotonic
solution.
Study of Regulatory Volume Decrease in Cystic Fibrosis
Mouse Cholangiocytes—To study the RVD of cholangiocytes in
the absence of Cftr, BDCCs isolated from Cftr/ mouse livers
were subjected to the same hypotonic challenges. As shown in
Fig. 1, exposure of the BDCCs from Cftr/ mouse livers
caused rapid swelling of cholangiocytes, indicated by a rapid
increase in the relative CSA to 1.20  0.01 of initial CSA (n 
53) in 10 min (Fig. 3). Compared with normal BDCCs, this
swelling of cholangiocytes from Cftr/ livers had a similar
time course and magnitude of increase in CSA in the swelling
phase. However, unlike in normal BDCCs, the relative CSA did
not return to the initial CSA and remained at 1.16  0.01 of
initial CSA after 40 min in the hypotonic solution, indicating
an impairment of RVD in CF mouse cholangiocytes (Fig. 3).
Effect of Potassium Ionophore on RVD—Given the fact that
RVD in normal cholangiocytes is dependent on both Cl and
FIG. 2. Immunofluorescent micrograph of normal and CF mouse BDCCs. Normal and CF mouse BDCCs were immuofluorescently
stained for CFTR. Whereas the normal mouse BDCC had bright immunofluorescent staining for CFTR (middle), the CF mouse BDCC (right) had
no significant immunofluorescent staining compared with negative control (left).
FIG. 3. Quantitative videomicro-
scopic measurements of normal and
CF mouse BDCC cross-sectional area
changes with hypotonic maneuver.
The CSAs of both normal and CF mouse
BDCCs, as measured by quantitative
videomicroscopy, increased by 20% with
hypotonic maneuver. Whereas the CSAs
of normal BDCCs returned toward their
initial sizes (6% in 40 min), those of CF
BDCCs did not return to their initial
sizes, indicating an impaired RVD in CF
mouse BDCCs.
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K conductances, as shown by our study using normal freshly
isolated mouse cholangiocytes (4) and others in the cholangio-
carcinoma cell line (3), this impaired RVD seen in CF mouse
cholangiocytes can be from defects either in Cl or K conduc-
tances. Although Cftr Cl channels provide major Cl conduc-
tances in cholangiocytes, previous electrophysiological studies
have characterized a number of other non-Cftr Cl channels
present and functioning in cholangiocytes (14, 15). Therefore,
we then studied the effect of valinomycin, a K ionophore, on
RVD in Cftr/ mouse cholangiocytes to examine whether
providing K conductance can rectify the impaired RVD in
these cells. Surprisingly, as shown in Fig. 4, an administration
of 1 M valinomycin completely restored the RVD in Cftr/
mouse BDCCs, and relative CSA returned to 1.05  0.01 (n 
35) (p  0.01 compared with negative control) of initial CSA in
40 min, whereas the CSA of untreated BDCCs did not show a
significant decrease. There was no significant change in cell
viability with valinomycin administration. Furthermore, co-
administration of valinomycin in normal mouse BDCCs during
hypotonic challenge had no significant effect on RVD compared
with controls (Fig. 5).
Characterization of Valinomycin-induced RVD in CF
Cholangiocytes—To further characterize the RVD seen in
Cftr/ BDCCs with valinomycin, the effect of a chloride chan-
FIG. 4. Effect of valinomycin on
RVD in CF mouse BDCCs. Coadminis-
tration of valinomycin (1 M), a potassium
ionophore, during hypotonic maneuver
normalized the impaired RVD in CF
mouse BDCCs, suggesting that the im-
paired RVD in CF cholangiocytes is prob-
ably due to a defect in K conductance to
provide a K efflux pathway.
FIG. 5. Effect of valinomycin on
RVD in normal mouse BDCCs. Coad-
ministration of valinomycin (1 M) during
hypotonic maneuver had no significant ef-
fect on RVD in normal mouse BDCCs
compared with the untreated controls.
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nel blocker, NPPB, on the valinomycin-induced RVD was stud-
ied to examine the specificity and dependence of Cl conduc-
tances during the observed RVD. As shown in Fig. 6, co-
administration of 10 M NPPB, in addition to 1 M
valinomycin, during hypotonic challenge completely inhibited
RVD. These results indicate that the RVD seen with valinomy-
cin is dependent on non-CFTR Cl conductance(s), which is
most likely a volume-activated chloride channel as shown by
our recent study in normal cholangiocytes (4). Again, there was
no significant change in viabilities of BDCCs, assessed by
trypan blue staining, in any of these groups. Taken together,
these results indicate that the limiting factor in the impaired
RVD seen in Cftr/ cholangiocytes is a defect not in Cl
conductances but in K conductances. Moreover, there are
other Cl conductances, which are functioning in Cftr/
cholangiocytes even with known CFTR defect and can mediate
RVD when K conductances are provided.
Effect of cAMP Agonists on RVD in CF Cholangiocytes—
Because stimulation of cAMP in certain cell types, such as
non-pigmented ciliary epithelial cells (16), has been shown to
enhance RVD, the effect of cAMP agonists on the impaired
RVD in CF cholangiocytes was examined. As shown in Fig. 7,
the administration of a cAMP agonist, isobutylmethylxanthine
(IBMX) (1 mM), during the hypotonic challenge had no signifi-
FIG. 6. Effect of NPPB on valinomy-
cin-induced RVD in CF mouse BD-
CCs. Coadministration of NPPB (10 M),
a general chloride channel blocker, with
valinomycin completely inhibited the va-
linomycin-induced RVD seen in CF BD-
CCs, indicating that it is not a nonspecific
effect of valinomycin but is dependent on
the functioning of the chloride channel(s).
FIG. 7. Effect of IBMX on RVD of CF
mouse BDCCs. Coadministration of
IBMX (1 mM) during hypotonic maneuver
had no significant effect on the RVD of
normal CF BDCCs.
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cant effect on the impaired RVD of BDCCs compared with that
of the untreated controls. In addition, the effect of a more
potent cAMP agonist, forskolin, on RVD of BDCCs was also
studied. As shown in Fig. 8, the RVD of BDCCs treated with
forskolin (10 M) (n  10) appeared to be slower in the initial
phase of RVD when compared with that of untreated controls
(n  18), but there was no statistically significant difference
between them. These findings indicate that, as previously
shown in normal cholangiocytes (4), the stimulation of CF
cholangiocytes with cAMP has no significant effect on the im-
paired RVD in CF cholangiocytes.
Effect of Calcium Agonists on RVD in CF Cholangiocytes—
The calcium pathway is known to be important for RVD in
many cell types, and stimulation of the calcium pathway in
certain cells has been shown to enhance RVD (16–22), al-
though RVD in certain cell types is not dependent on calcium
(23–26). To examine whether an increase in intracellular cal-
cium can rectify the impaired RVD in CF cholangiocytes, the
effect of calcium agonists on the RVD in CF BDCCs was stud-
ied. As shown in Figs. 9 and 10, the administration of calcium
agonists, thapsigargin (2 M) or ionomycin (1 M), respectively,
during the hypotonic challenge had no significant effect on
FIG. 8. Effect of forskolin on RVD of
CF mouse BDCCs. Coadministration of
forskolin (10 M) during hypotonic ma-
neuver had no significant effect on the
RVD of normal CF BDCCs.
FIG. 9. Effect of thapsigargin on
RVD of CF mouse BDCCs. Coadminis-
tration of thapsigargin (2 M) during hy-
potonic maneuver had no significant ef-
fect on the RVD of CF mouse BDCCs.
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RVD in CF BDCCs. These findings indicate that unlike some
other cell types, the stimulation of CF cholangiocytes with
calcium agonists had no significant effect on the impaired RVD
observed in CF cholangiocytes.
DISCUSSION
In this manuscript, we report the first successful isolation
and use of intact intrahepatic bile duct fragments from CF
mouse liver using the mouse intrahepatic bile duct unit isola-
tion method developed and reported recently (4, 6). Although
previously we have extensively used IBDUs with enclosed lu-
men for biliary secretion studies, in this study we have ex-
cluded those IBDUs and used only those bile duct cell clusters
without lumen to simplify cell volume measurements without
interference from changes in lumen volume with hypotonic
challenge. These BDCCs are determined to be of biliary origin
by positive immunocytochemistry using a cholangiocyte spe-
cific cytokeratin-19 antibody. In addition, the mouse BDCCs
from normal mouse livers had a bright CFTR immunostaining,
whereas the CF BDCCs had no significant immunostaining
compared with negative controls (Fig. 2). Previous electron
microscopic studies demonstrated that these cell clusters con-
sisted of typical cholangiocytes, resembling previous morpho-
logic descriptions of isolated rat cholangiocytes (27, 28) or rat
and mouse IBDUs (6, 11, 29) with large, lobulated, basally
situated nuclei and sparse mitochondria. Unlike rat IBDUs but
like mouse IBDUs, these BDCCs have less connective tissue
around them, and the mouse cholangiocytes exhibit a more
refractory pattern by light microscopy using Nomarski optics.
Thus, it is easier to outline the borders of these mouse BDCCs
to measure CSAs than those of rat IBDUs.
To assess cell volume changes with hypotonic challenges, we
have used CSA as an indirect measure of cell volume as have
other investigators for cholangiocytes (12) or for other cell types
(13). In addition, we recently have shown and validated that
the CSA measurements of mouse BDCCs obtained by quanti-
tative videomicroscopy were highly correlated (linear correla-
tion coefficient, r2  0.94) with the cell volume measurements
by 3 independent methods: 1) sequential Nomarski light, 2)
fluorescence microscopy of BDCCs loaded with BCECF and
computer-assisted measurements of the corresponding CSA
and volumes, and 3) laser-scanning confocal microscopy of in-
tracellular fluorescent dye, BCECF-loaded BDCCs, and com-
puter-assisted three-dimensional reconstruction and volume
calculation (4).
As previously reported, in Mz-ChA-1 cells from human
cholangiocarcinoma cell lines (3) and in freshly isolated BDCCs
(4), cholangiocytes have intact RVD, which is important for this
active epithelium to cope with changes in osmolarity from
absorption and secretion of ions and substances. However, we
now show that BDCCs from CF mouse livers have an impaired
RVD, which has important implications for various vital cellu-
lar functions such as hepatobiliary metabolism, ion transport,
bile secretion, and gene expression (30). Furthermore, RVD is
shown to stimulate bile flow and bile salt secretion in isolated
perfused rat livers (31), and cell volume regulation is thought
to play a critical role in bile secretion, thus this impaired RVD
in CF cholangiocytes may directly contribute to the pathophys-
iologic mechanisms underlying the biliary cholestatic liver dis-
eases seen in CF patients. In fact, there is some literature
indicating that coupled regulatory volume increase and RVD
may provide underlying ion transport mechanisms in secretory
epithelia (32–34).
Because the RVD seen in cholangiocytes is mediated by
chloride and potassium conductances, as demonstrated in hu-
man cholangiocarcinoma cell lines (3) and in freshly isolated
normal BDCCs (4), the observed impaired RVD in CF cholan-
giocytes can be from either defective chloride or potassium
conductances. Contrary to our initial reasoning that the defi-
cient chloride conductance from the absence of CFTR chloride
channel accounts for the observed impaired RVD, the results
that valinomycin, a potassium ionophore, rectified the im-
paired RVD in CF cholangiocytes indicate that the rate-limit-
ing defect is not chloride conductance but potassium conduct-
ance. These results provide the first compelling evidence that
CFTR has regulatory interactions on potassium conductance(s)
responsible for the RVD in cholangiocytes as shown in other
cell types (35). In fact, CFTR is known to function as both a
chloride channel and an epithelial transport regulator, inter-
FIG. 10. Effect of ionomycin on RVD
of CF mouse BDCCs. Coadministration
of ionomycin (1 M) during hypotonic ma-
neuver had no significant effect on the
RVD of CF mouse BDCCs.
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acting with various sodium (36) and chloride (37–39) channels,
as well as potassium channels (40, 41). Although the identity of
the potassium conductance pathway(s) responsible for the RVD
in CF cholangiocytes is not clear, our previous study in normal
cholangiocytes (4) provides some helpful clue that it is most
likely a tetraethylammonium chloride-resistant but barium
chloride-inhibitable potassium conductance pathway(s) assum-
ing that the same ion transport pathways are functional in CF
cholangiocytes. A recent study using human cholangiocarci-
noma Mz-ChA-1 cells identified apamin-sensitive SKCa chan-
nels as a potential potassium conductive pathway mediating
the RVD in cholangiocytes (42). However, the present study
indicates that calcium agonists could not overcome the im-
paired RVD in CF cholangiocytes even though such an increase
in intracellular calcium was expected to stimulate the SKCa
channels, unless the activation of SKCa channels requires the
presence of functioning CFTR in the cholangiocytes. In addi-
tion, calcium agonists had no significant effect on RVD in
normal cholangiocytes.2 Therefore, the role of the calcium-
activated ion transport pathway(s) in RVD in cholangiocytes is
not entirely clear, and further study is needed.
The precise underlying mechanism(s) for the defect in RVD
in CF mouse cholangiocytes is not clearly characterized, but
some recent studies in various cell types propose an important
role of ATP in cell volume regulation (43–46). Although it is
somewhat controversial whether the CFTR can conduct ATP or
regulate ATP-conducting pathways, ATP transported out of the
cell during RVD is thought to interact with the purinergic
receptor pathway to bring about cell volume regulation (43–
46). Therefore, an administration of extracellular ATP to the
CF cells should restore RVD as shown in CF mouse renal cells
(47, 48). However, no clear cause-and-effect relationship was
observed with the ATP release and the VACC activation in the
human intestinal epithelial cell line lacking CFTR (49) or in the
murine mammary carcinoma cell line (50). Thus, further stud-
ies are needed to determine the precise underlying mechanisms
of RVD in CF cholangiocytes and the role of extracellular ATP
in RVD and its effect on VACC in CF cholangiocytes.
It is also notable that the valinomycin-induced RVD in CF
cholangiocytes is faster than RVD in normal cholangiocytes,
which may suggest that the rate-limiting step of the RVD in
normal cholangiocytes also may be potassium conductance.
However, an alternative explanation is that the expression of
CFTR in normal cholangiocytes may have some inhibitory reg-
ulatory influence on VACCs, as it has been shown recently that
an ATP-hydrolyzable conformation of NBD2 is essential for the
regulation of the VACC by the CFTR (39, 51). This explanation
is also supported by the fact that the administration of valino-
mycin during the RVD in normal cholangiocytes does not in-
crease the rate of RVD in normal cholangiocytes (Fig. 5), argu-
ing against the explanation that the rate-limiting step in RVD
in normal cholangiocytes is potassium conductance. Thus, the
absence of functional CFTR in CF cholangiocytes may lead to
loss of its inhibitory influence on VACCs, which is reflected by
the faster RVD in CF cholangiocytes induced by valinomycin
than the RVD in normal cholangiocytes.
Moreover, the correction of the impaired RVD in CF cholan-
giocytes with the administration of valinomycin was not due to
nonspecific effects of the potassium ionophore but was com-
pletely inhibited by NPPB, a general chloride channel blocker,
demonstrating an involvement of the NPPB-inhibitable chlo-
ride conductive pathway(s) in this RVD. Although we cannot
definitively rule out the nonspecific effect of NPPB, we have
used NPPB at a relatively low (10 M) concentration in an
attempt to minimize nonspecific effects of NPPB, and we have
not observed any changes in cell morphologies or viabilities by
trypan blue exclusion at the end of the experiments. Consider-
ing the fact that both chloride and potassium efflux are re-
quired for RVD in cholangiocytes (3, 4), the observed inhibition
of NPPB on the valinomycin-induced RVD in CF cholangiocytes
may be from its well known inhibitory effect on the chloride
channel or from its possible but less likely nonspecific inhibi-
tory effect on the potassium channel. However, any possible
nonspecific inhibitory effect of NPPB on the potassium channel
has no significant bearing here because valinomycin, a potas-
sium ionophore, should have provided an alternative potas-
sium conductive pathway to bypass such inhibition. Thus, even
if NPPB inhibited the potassium channel, it cannot account for
the observed inhibitory effect of NPPB on the valinomycin-
induced RVD in CF cholangiocytes. Therefore, the most logical
conclusion is that NPPB-inhibited chloride efflux is required
for the valinomycin-induced RVD in CF cholangiocytes. These
findings together, in turn, support our conclusion that the loss
of CFTR function in CF cholangiocytes resulted in the defective
potassium conductive pathway responsible for RVD.
Furthermore, these results provide evidence for the presence
of a non-CFTR chloride conductive pathway(s) functioning in
CF cholangiocytes. Previously, a number of non-CFTR chloride
channels have been characterized in cholangiocytes, such as
the calcium-activated chloride channel, volume-activated chlo-
ride channel, and high conductance anion channel (3, 14, 52).
However, it was not known whether any of these non-CFTR
chloride channels were functioning in CF cholangiocytes. Thus,
the present finding provides the first evidence that an NPPB-
inhibitable non-CFTR chloride channel(s) is functioning to me-
diate RVD in CF cholangiocytes. Such a chloride conductive
pathway(s) can provide an alternative chloride conductive
pathway to compensate for the absence of a CFTR chloride
channel in the CF biliary epithelium, knowledge that is poten-
tially useful for developing therapies for CF cholestatic liver
diseases.
In the present study, cAMP agonists were employed in an
attempt to correct for the impaired RVD in CF cholangiocytes
because cAMP is shown to stimulate RVD in some cell types
(16, 53). However, neither IBMX nor forskolin had any signif-
icant stimulatory effect on RVD in CF cholangiocytes, and they
could not reverse the impaired RVD in CF cholangiocytes. This
result is consistent with our findings in normal cholangiocytes
that cAMP agonists had no stimulatory effect on RVD (4).
Instead, forskolin had a mild inhibitory effect on RVD in nor-
mal cholangiocytes (4) as shown in myocytes (54), whereas
IBMX had no significant effect on RVD in normal cholangio-
cytes (4). Although the mechanism underlying this inhibitory
effect of forskolin on RVD seen in normal cholangiocytes is not
clear, it is possibly from its inhibitory effect on VACCs as
shown in myocytes (54). Thus, the measures to stimulate the
cAMP pathway(s) by potent cAMP agonists to overcome the
defective CFTR chloride channels in CF cholangiocytes may be
counterproductive because of their possible inhibitory effect on
cell volume regulation in cholangiocytes, critical for biliary
secretion.
The calcium pathway plays an important role in cell volume
regulation in many cell types (17, 18, 20, 22) whereas in some
cell types, RVD is not dependent on calcium (23–26). In addi-
tion, in some cells such as cerebellar astrocytes (55), RVD and
changes in intracellular calcium are not related. Thus intracel-
lular calcium is thought to be irrelevant as a transduction
signal for RVD, whereas an increase in intracellular calcium in
certain cells such as human non-pigmented ciliary epithelial
cells (16) has been shown to enhance RVD. A recent patch-2 W. K. Cho, V. J. Siegrist, and W. Zinzow, manuscript in preparation.
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clamping study demonstrated the important role of SKCa
channel-mediating RVD in cholangiocytes (42), thus an in-
crease in intracellular calcium was expected to help reverse the
impaired RVD in CF cholangiocytes. However, neither ionomy-
cin nor thapsigargin had any significant effect on the impaired
RVD in CF cholangiocytes, suggesting that the stimulation of a
calcium-dependent pathway(s) cannot compensate for the im-
paired RVD in CF cholangiocytes. These results are consistent
with the findings in normal cholangiocytes that calcium ago-
nists had no significant effect on the RVD in normal BDCCs.2
Therefore, the role of calcium in RVD in cholangiocytes is not
clear, but these results suggest that calcium-dependent path-
ways do not appear to play a major role in RVD in cholangio-
cytes. Alternatively, the defect from CFTR loss may be a down-
stream event from calcium signal. Further studies are needed
to clarify the precise role of calcium-dependent pathways in
RVD in cholangiocytes.
As a summary, the present study demonstrates for the first
time that cholangiocytes from CF mouse liver have an impaired
cell volume regulation and that this impaired RVD is most
likely from the defect in potassium conductance in the absence
of CFTR, which may serve an important pathophysiological
mechanism for CF cholestatic liver disease. Moreover, our in-
direct evidence indicates that the volume-activated chloride
conductance pathway(s) is functional in CF cholangiocytes, and
that such a pathway(s) can potentially provide an alternative
chloride conductance pathway necessary to compensate for the
absence of functional CFTR chloride conductance in CF cholan-
giocytes to overcome biliary secretory defect in CF liver
diseases.
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